AKBA - Analyst Highly Confident In Akebia Therapeutics' Kidney Disease-Associated Anemia Drug Stock Soars | Benzinga
HC Wainwright has upgraded Akebia Therapeutics Inc (NASDAQ: AKBA) from Neutral to Buy rating.
Analysts Ed Arce and Thomas Yip note that the company last week received the official minutes from the End-of-Dispute Type A meeting held with the FDA in late July.
Akebia Therapeutics expects to resubmit its New Drug Application (NDA) for vadadustat for anemia due to chronic kidney disease in adult patients on dialysis by the end of Q3 of 2023, with a potential action date projected in March 2024.
HC Wainwright says ...